ストックスクリーナーアプリを入手
6.23
1.74%
-0.11
アフターアワーズ：
6.39
0.16
+2.57%
前日終値:
$6.34
開ける：
$6.39
24時間の取引高:
1.38M
Relative Volume:
0.80
時価総額：
$1.08B
収益：
$291.85M
当期純損益:
$554.00K
株価収益率:
-819.74
EPS:
-0.0076
ネットキャッシュフロー:
$27.93M
1週間 パフォーマンス:
+2.30%
1か月 パフォーマンス:
+3.15%
6か月 パフォーマンス:
-36.88%
1年 パフォーマンス:
+34.27%
1日の値動き範囲:
$6.21
$6.465
1週間の範囲:
$5.97
$6.465
52週間の値動き範囲:
$4.255
$10.08
Xeris Biopharma Holdings Inc Stock (XERS) Company Profile
名前
Xeris Biopharma Holdings Inc
セクター
電話
844-445-5704
住所
1375 WEST FULTON STREET, SUITE 1300, CHICAGO, IL
Compare XERS vs TAK, ZTS, TEVA, HLN, UTHR
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
XERS
Xeris Biopharma Holdings Inc
|
6.23 | 1.09B | 291.85M | 554.00K | 27.93M | -0.0076 |
TAK
Takeda Pharmaceutical Co Adr
|
16.55 | 52.32B | 29.85B | 776.90M | 4.35B | 0.2408 |
ZTS
Zoetis Inc
|
112.54 | 47.38B | 9.47B | 2.67B | 2.28B | 6.0218 |
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
35.86 | 41.16B | 17.53B | 1.58B | 444.18M | 1.3457 |
HLN
Haleon Plc Adr
|
9.17 | 41.02B | 14.54B | 2.22B | 2.58B | 0.4871 |
UTHR
United Therapeutics Corp
|
572.20 | 24.67B | 3.18B | 1.33B | 1.04B | 27.90 |
Xeris Biopharma Holdings Inc Stock (XERS) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2025-12-09 | 開始されました | Barclays | Overweight |
| 2025-08-12 | 再開されました | H.C. Wainwright | Buy |
| 2024-11-11 | ダウングレード | Piper Sandler | Overweight → Neutral |
| 2024-03-28 | 開始されました | Oppenheimer | Outperform |
| 2023-08-28 | 開始されました | Craig Hallum | Buy |
| 2022-10-21 | 開始されました | Jefferies | Buy |
| 2022-04-28 | 開始されました | Craig Hallum | Buy |
| 2021-11-17 | 開始されました | SVB Leerink | Outperform |
| 2021-10-29 | 開始されました | H.C. Wainwright | Buy |
| 2021-04-07 | 再開されました | RBC Capital Mkts | Outperform |
| 2020-02-18 | 開始されました | Piper Sandler | Overweight |
| 2018-07-16 | 開始されました | Jefferies | Buy |
| 2018-07-16 | 開始されました | Leerink Partners | Outperform |
| 2018-07-16 | 開始されました | RBC Capital Mkts | Outperform |
すべてを表示
Xeris Biopharma Holdings Inc (XERS) 最新ニュース
Insider Sell Alert: Beth Hecht Sells 16,667 Shares of Xeris Biop - GuruFocus
Insider Sell Alert: Beth Hecht Sells 16,667 Shares of Xeris Biopharma Holdings Inc (XERS) - GuruFocus
Beth Hecht Sells 16,667 Shares of Xeris Biopharma (NASDAQ:XERS) Stock - MarketBeat
Xeris Biopharma’s chief legal officer sells $103,805 in stock - Investing.com
Xeris Biopharma (XERS) officer sells 16,667 shares under 10b5-1 plan - Stock Titan
Xeris Biopharma (XERS) to Release Earnings on Thursday - MarketBeat
Xeris Biopharma Reports Third Quarter 2024 Financial Results - Quantisnow
Xeris Biopharma Holdings, Inc. (XERS) Hit a 52 Week High, Can the Run Continue? - MSN
Xeris Biopharma expects full-year 2025 revenue above estimates - MSN
Xeris Biopharma Holdings, Inc. (NASDAQ:XERS) Receives Average Rating of "Moderate Buy" from Analysts - MarketBeat
Xeris Biopharma to Report First Quarter 2026 Financial Results on May 7, 2026 - BioSpace
Xeris Biopharma Holdings, Inc. ($XERS) CEO 2025 Pay Revealed - Quiver Quantitative
[ARS] Xeris Biopharma Holdings, Inc. SEC Filing - Stock Titan
Xeris Biopharma (NASDAQ: XERS) details 2026 votes on pay, board, auditor - Stock Titan
Xeris (XERS) Year-Ahead Outlook | Q4 2025: EPS Exceeds ExpectationsDark Pool - Cổng thông tin điện tử Tỉnh Sơn La
Xeris Biopharma director Jeffrey Sherman to retire after 2026 annual meeting - Investing.com India
Xeris Biopharma director Jeffrey Sherman to retire after 2026 annual meeting By Investing.com - Investing.com South Africa
Xeris Biopharma Announces Board Transition as Director Retires - TipRanks
Xeris Biopharma's Jeffrey Sherman to Retire from Board - TradingView
Director Jeffrey Sherman to retire from Xeris Biopharma (XERS) board in 2026 - Stock Titan
Xeris Biopharma stock (US98422E1038): Is its rare disease focus strong enough to drive sustained gro - AD HOC NEWS
Xeris Biopharma stock (US98422E1038): Is its rare disease focus strong enough to unlock new upside? - AD HOC NEWS
Xeris Biopharma Holdings, Inc. $XERS Shares Sold by Tudor Investment Corp ET AL - MarketBeat
Xeris Biopharma Holdings, Inc. (XERS) Stock Analysis: Uncovering an 82% Potential Upside in the Biotech Sector - DirectorsTalk Interviews
Xeris (XERS) Stock: Investment Decision (+2.14%) 2026-04-15Community Watchlist - UBND thành phố Hải Phòng
Record Profitability, 2026 Growth Outlook and Recorlev Patent Suit Might Change The Case For Investing In Xeris Biopharma Holdings (XERS) - Sahm
Barclays Initiates Coverage on Xeris Biopharma Holdings (XERS) w - GuruFocus
XERS.O Stock News Today | Earnings, Events & Price Alerts - Intellectia AI
Does Record Q4 Results, Robust 2026 Guidance and Recorlev Patent Suit Change The Bull Case For Xeris (XERS)? - Yahoo Finance
Is Xeris (XERS) Stock Overvalued Now | Price at $5.87, Up 0.26%Expert Market Insights - Cổng thông tin điện tử tỉnh Lào Cai
XERS.O Technical Analysis & Stock Price Forecast - Intellectia AI
Earnings Recap: Why is Xeris Biopharma Holdings Inc stock going upWeekly Stock Summary & Verified Short-Term Trading Plans - baoquankhu1.vn
What limits growth of Xeris (XERS) Stock | XERS Q4 Earnings: Beats Estimates by $0.02Revenue Growth Rate - Xã Thanh Hà
Q1 2025 Xeris Biopharma Holdings Inc Earnings Call Transcript - GuruFocus
XERS Should I Buy - Intellectia AI
XERS Financials: Revenue Breakdown, Margins & Competitor Comparison - Intellectia AI
Apella Capital LLC Acquires 235,897 Shares of Xeris Biopharma Holdings, Inc. $XERS - MarketBeat
A Look At Xeris Biopharma Holdings (XERS) Valuation After Its Q4 2025 Earnings Beat - Sahm
Should I Buy Xeris (XERS) Stock Today | Price at $6.05, Up 0.17%Value Ideas - Xã Thanh Hà
Xeris Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)April 3, 2026 - BioSpace
Oppenheimer Maintains Xeris Biopharma Holdings (XERS) Outperform Recommendation - MSN
XERS Technical Analysis & Stock Price Forecast - Intellectia AI
Xeris Biopharma (NASDAQ:XERS) Insider Sells $99,835.33 in Stock - MarketBeat
Beth Hecht Sells 16,667 Shares of Xeris Biopharma Holdings Inc (XERS) - GuruFocus
Xeris Biopharma Approves Inducement Grants for 50,000 Shares to Two New Employees - geneonline.com
Xeris Biopharma Holdings Inc (XERS) 財務データ
収益
当期純利益
現金流量
EPS
0.67%
2.13%
大文字化:
|
ボリューム (24 時間):